This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kayastha, S. Articles by Werness, B. A. Search for Related Content PubMed PubMed Citation Articles by Kayastha, S. Articles by Werness, B. A.

Expression of the Hyaluronan Receptor, CD44S, in Epithelial Ovarian Cancer Is an Independent Predictor of Survival

Division of Pathology [S. K., J. M., M. R-G., B. A. W.] and Department of Gynecologic Oncology [M. S. P.], Roswell Park Cancer Institute, Buffalo, New York 14263, and Applied Research Branch, National Cancer Institute, Bethesda, Maryland 20892 [A. N. F.]

Most ovarian carcinomas present at advanced stage, principally as the result of dissemination to peritoneal sites. Standard CD44 (CD44S) is the principal receptor for hyaluronic acid, and in vitro and animal studies have suggested that the attachment of ovarian carcinoma cells to the peritoneal mesothelium involves the interaction between CD44S on ovarian carcinoma cells and hyaluronic acid on mesothelial surfaces. We, therefore, analyzed a series of ovarian carcinomas for the expression of CD44S by immunohistochemistry to see whether expression of this receptor by tumor cells correlated with clinicopathological factors and measures of patient outcome. Fifty-six fixed, paraffin-embedded primary epithelial ovarian tumors were immunostained with antibody to CD44S. Membrane staining was considered positive, and results were correlated with stage, grade, age, histology, and survival. Twenty-two (39%) tumors were positive for CD44S. There was no correlation between CD44 expression and histological type, grade, age, or stage. However, CD44 expression was significantly associated with survival in both univariate (P = 0.003) and multivariate (P = 0.006) analyses. These results support a role for CD44S expression in the spread of ovarian epithelial cancer and suggest that expression of this molecule is a significant independent predictor of survival in women with this disease.

This article has been cited by other articles:

				A. Banzato, S. Bobisse, M. Rondina, D. Renier, F. Bettella, G. Esposito, L. Quintieri, L. Melendez-Alafort, U. Mazzi, P. Zanovello, et al. A Paclitaxel-Hyaluronan Bioconjugate Targeting Ovarian Cancer Affords a Potent In vivo Therapeutic Activity Clin. Cancer Res., June 1, 2008; 14(11): 3598 - 3606. [Abstract] [Full Text] [PDF]

				S. Sillanpaa, M. A. Anttila, K. Voutilainen, R. H. Tammi, M. I. Tammi, S. V. Saarikoski, and V.-M. Kosma CD44 Expression Indicates Favorable Prognosis in Epithelial Ovarian Cancer Clin. Cancer Res., November 1, 2003; 9(14): 5318 - 5324. [Abstract] [Full Text] [PDF]